Using rifapentine to prevent tuberculosis in various populations
Short-course rifapentine for TB prevention for all: clinical pharmacology matters
This study is looking at how well a short treatment with rifapentine can help prevent tuberculosis in people who are at higher risk, like children, pregnant women, and those living with HIV, to make sure the treatment is safe and works effectively for them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11006936 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a short-course treatment using rifapentine to prevent tuberculosis (TB) in high-risk groups, including children, pregnant women, and people living with HIV. The study aims to determine the optimal dosing of rifapentine and other TB medications through pharmacokinetic assessments, ensuring that these treatments are safe and well-tolerated. By enrolling participants from these priority populations, the research seeks to confirm that the treatment achieves the necessary drug exposure levels for effective prevention. The approach includes careful monitoring and modeling to understand how different factors affect drug absorption and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research include children under 12 years old, pregnant women, and individuals living with HIV who are taking dolutegravir.
Not a fit: Patients who are not in the specified high-risk groups or those not taking dolutegravir may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective TB prevention strategies for vulnerable populations.
How similar studies have performed: Previous research has shown promise in using rifapentine for TB prevention, but this specific approach focusing on high-risk populations is novel.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Dooley, Kelly E. — Vanderbilt University Medical Center
- Study coordinator: Dooley, Kelly E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.